264 related articles for article (PubMed ID: 18753118)
1. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
HIV Clin Trials; 2008; 9(4):238-46. PubMed ID: 18753118
[TBL] [Abstract][Full Text] [Related]
2. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
González-García J; Cohen D; Johnson M; Sloan L; Fredrick L; Naylor C; da Silva B; Bernstein B;
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):841-5. PubMed ID: 20672994
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
5. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
[TBL] [Abstract][Full Text] [Related]
6. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Broder MS; Chang EY; Bentley TG; Juday T; Uy J
J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
[TBL] [Abstract][Full Text] [Related]
8. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
[TBL] [Abstract][Full Text] [Related]
9. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
10. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Polk C; Chan-Tack KM; Kopack AM; Amoroso A
AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655
[No Abstract] [Full Text] [Related]
11. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008
[TBL] [Abstract][Full Text] [Related]
12. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
13. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
14. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
15. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
[TBL] [Abstract][Full Text] [Related]
16. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Parienti JJ; Barrail-Tran A; Duval X; Nembot G; Descamps D; Vigan M; Vrijens B; Panhard X; Taburet AM; Mentré F; Goujard C
Antimicrob Agents Chemother; 2013 May; 57(5):2265-71. PubMed ID: 23459496
[TBL] [Abstract][Full Text] [Related]
17. An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M
AIDS Patient Care STDS; 2008 Apr; 22(4):263-6. PubMed ID: 18422459
[No Abstract] [Full Text] [Related]
18. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapies in women after single-dose nevirapine exposure.
Lockman S; Hughes MD; McIntyre J; Zheng Y; Chipato T; Conradie F; Sawe F; Asmelash A; Hosseinipour MC; Mohapi L; Stringer E; Mngqibisa R; Siika A; Atwine D; Hakim J; Shaffer D; Kanyama C; Wools-Kaloustian K; Salata RA; Hogg E; Alston-Smith B; Walawander A; Purcelle-Smith E; Eshleman S; Rooney J; Rahim S; Mellors JW; Schooley RT; Currier JS;
N Engl J Med; 2010 Oct; 363(16):1499-509. PubMed ID: 20942666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
